ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0356

Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

Anca Askanase1, Lucy Hodge2, Vanessa Birardi3 and Henry Leher3, 1Columbia University Medical Center, New York, NY, 2Aurinia Pharmaceuticals, Seattle, WA, 3Aurinia Pharmaceuticals Inc, Rockville, MD

Meeting: ACR Convergence 2022

Keywords: clinical trial, Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Voclosporin, a novel calcineurin inhibitor, is approved for the treatment of adults with lupus nephritis in combination with background immunotherapy and was successfully tested in two pivotal trials, AURA-LV (Phase 2) and AURORA 1 (Phase 3). Pooled data from these trials showed that adding voclosporin to mycophenolate mofetil (MMF) and low-dose steroids resulted in significantly more patients achieving urine protein creatinine ratio (UPCR) reductions of ≥50% from baseline at one year; the median time to this endpoint was also significantly shorter in the voclosporin arm.

As reduced proteinuria at one year is the best predictor of improved long-term renal outcomes in lupus nephritis, we have analyzed the impact of voclosporin on the time to proteinuria reduction by biopsy class in pooled data from the AURA-LV and AURORA 1 trials.

Methods: Both trials enrolled patients with biopsy-proven lupus nephritis (Class III, IV, or V ± III/IV), proteinuria ≥1.5 mg/mg (≥2 mg/mg for Class V) and estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m2. The pooled analysis included 268 and 266 patients in the voclosporin and control arms, respectively. All patients received MMF (target 2 g/day) and steroids (target dose 2.5 mg/day by Week 16). For this post-hoc analysis, hazard ratios (HR) for the times to UPCR ≤0.5 mg/mg and UPCR reduction ≥50% from baseline were analyzed by biopsy class.

Results: Voclosporin resulted in faster times to both UPCR ≤0.5 mg/mg and UPCR reduction ≥50% from baseline in the overall study population and across individual biopsy classes (HR >1; Table 1). Median times to UPCR ≤0.5 mg/mg and UPCR reduction ≥50% from baseline for patients with pure Class III disease were significantly shorter for voclosporin-treated patients than control: 142 vs 372 days and 25 vs 84 days, respectively. The median time to UPCR reduction ≥50% was faster in pure Class IV patients treated with voclosporin as well (29 vs 57 days); voclosporin-treated patients achieved a UPCR ≤0.5 mg/mg in a median of 142 days while in the control arm, more than 50% of patients did not achieve this endpoint during the one-year study. Differences between voclosporin and control arms for Class III and Class IV were apparent within the first month of treatment and sustained at one year (Figures 1, 2). Patients with pure Class V disease took the longest to achieve both endpoints; the difference between arms was not statistically significant.

Conclusion: The addition of voclosporin to MMF and low-dose steroids resulted in earlier reductions in proteinuria across all biopsy classes. This analysis supports the efficacy results observed in the individual AURA-LV and AURORA 1 trials, indicating faster time to response, when voclosporin is added to standard of care agents MMF and steroids.

Supporting image 1

Post hoc analysis of time to UPCR endpoints includes pooled data from the 23.7 mg BID voclosporin arms and control arms in AURA-LV and AURORA 1. Data include up to 48 weeks from AURA-LV and up to 52 weeks from AURORA 1. Patients with mixed Class III/V or IV/V are included in the overall analysis but not the individual analyses for pure Class III, Class IV, or Class V.
a) Includes all biopsy classes in AURORA 1 and AURA-LV.
b) p-value vs control.
c) Values not determinable due to either the endpoint not being met by 50% of the cohort within the study period or limited additional patients achieving the endpoint after the median timepoint but before the end of the study.
CI, confidence interval; HR, hazard ratio; ND, not determinable; UPCR, urine protein creatinine ratio.

Supporting image 2

Post-hoc analysis of time to UPCR endpoints includes pooled data from the 23.7 mg BID voclosporin arms and control arms in AURA-LV and AURORA 1. Data include up to 48 weeks from AURA-LV and 52 weeks from AURORA 1. UPCR, urine protein creatinine ratio.

Supporting image 3

Post-hoc analysis of time to UPCR endpoints includes pooled data from the 23.7 mg BID voclosporin arms and control arms in AURA-LV and AURORA 1. Data include up to 48 weeks from AURA-LV and 52 weeks from AURORA 1. UPCR, urine protein creatinine ratio.


Disclosures: A. Askanase, AstraZeneca, GlaxoSmithKlein(GSK), Aurinia, Amgen, Pfizer, Idorsia, Eli Lilly, UCB, AbbVie/Abbott, Janssen, Bristol-Myers Squibb(BMS); L. Hodge, Aurinia Pharmaceuticals; V. Birardi, Aurinia Pharmaceuticals; H. Leher, Aurinia Pharmaceuticals.

To cite this abstract in AMA style:

Askanase A, Hodge L, Birardi V, Leher H. Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/early-reductions-in-proteinuria-with-voclosporin-treatment-across-lupus-nephritis-biopsy-classes-pooled-data-from-the-aura-lv-and-aurora-1-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-reductions-in-proteinuria-with-voclosporin-treatment-across-lupus-nephritis-biopsy-classes-pooled-data-from-the-aura-lv-and-aurora-1-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology